PMID- 34286250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210722
IS  - 2617-0205 (Electronic)
IS  - 2617-0191 (Print)
IS  - 2617-0191 (Linking)
VI  - 25
IP  - 2
DP  - 2019
TI  - Manipulation of autophagy for host-directed tuberculosis therapy.
LID - 10.7196/AJTCCM.2019.v25i2.014 [doi]
AB  - Mycobacterium tuberculosis (M. tb) is one of the world's most successful human 
      pathogens, infecting ~2 billion people worldwide. Although there are effective 
      drugs against M. tb., the disease remains out of control owing to prolonged and 
      toxic treatment. Shorter regimens are urgently required to control TB. 
      Drug-resistant TB (DR-TB) also threatens to derail TB control. These unfulfilled 
      needs could be addressed by the identification and development of host-directed 
      therapeutic agents for TB. Manipulation of the innate immune response, including 
      autophagy, may lead to the identification of cellular pathways that could be 
      exploited to develop host-directed therapeutic interventions. Host-directed 
      therapies (HDTs) aim to augment immune mechanisms against M. tb infection and/or 
      reduce excess inflammation, thus preventing end-organ tissue damage, preserving 
      lung function and/or enhancing the effectiveness of TB drug therapy in 
      eliminating infection. HDTs may also have additional advantages for patients with 
      TB/HIV co-infection, as HDTs may reduce the risk of interaction with 
      antiretroviral drugs and the risk of developing immune reconstitution 
      inflammatory syndrome (IRIS) and death. In this review, we discuss the role of 
      autophagy as a potential pathway that could be exploited as a host-directed TB 
      therapeutic agent.
FAU - Gina, P
AU  - Gina P
AD  - Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung 
      Institute, Department of Medicine, University of Cape Town, South Africa.
FAU - Davids, M
AU  - Davids M
AD  - Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung 
      Institute, Department of Medicine, University of Cape Town, South Africa.
FAU - Dheda, K
AU  - Dheda K
AD  - Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung 
      Institute, Department of Medicine, University of Cape Town, South Africa.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190731
PL  - South Africa
TA  - Afr J Thorac Crit Care Med
JT  - African journal of thoracic and critical care medicine
JID - 101751995
PMC - PMC8278992
OTO - NOTNLM
OT  - autophagy
OT  - host directed tuberculosis therapy
OT  - mycobacterium tuberculosis
COIS- Conflicts of interest: None.
EDAT- 2019/07/31 00:00
MHDA- 2019/07/31 00:01
PMCR- 2019/07/31
CRDT- 2021/07/21 06:40
PHST- 2019/06/06 00:00 [accepted]
PHST- 2021/07/21 06:40 [entrez]
PHST- 2019/07/31 00:00 [pubmed]
PHST- 2019/07/31 00:01 [medline]
PHST- 2019/07/31 00:00 [pmc-release]
AID - 10.7196/AJTCCM.2019.v25i2.014 [doi]
PST - epublish
SO  - Afr J Thorac Crit Care Med. 2019 Jul 31;25(2):10.7196/AJTCCM.2019.v25i2.014. doi: 
      10.7196/AJTCCM.2019.v25i2.014. eCollection 2019.